NASDAQ:RYTM Rhythm Pharmaceuticals - RYTM Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $17.66 +0.22 (+1.26%) (As of 03/30/2023 04:00 PM ET) Add Compare Share Share Today's Range$16.90▼$18.0450-Day Range$16.88▼$31.1452-Week Range$3.04▼$34.99Volume1.19 million shsAverage Volume639,509 shsMarket Capitalization$1.00 billionP/E RatioN/ADividend YieldN/APrice Target$36.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Rhythm Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside103.9% Upside$36.00 Price TargetShort InterestBearish15.03% of Float Sold ShortDividend StrengthN/ASustainability-1.80Upright™ Environmental ScoreNews Sentiment0.48Based on 7 Articles This WeekInsider TradingSelling Shares$172,045 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.95) to ($2.02) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.39 out of 5 starsMedical Sector216th out of 999 stocksPharmaceutical Preparations Industry88th out of 489 stocks 4.3 Analyst's Opinion Consensus RatingRhythm Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $36.00, Rhythm Pharmaceuticals has a forecasted upside of 103.9% from its current price of $17.66.Amount of Analyst CoverageRhythm Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted15.03% of the float of Rhythm Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRhythm Pharmaceuticals has a short interest ratio ("days to cover") of 12.1, which indicates bearish sentiment.Change versus previous monthShort interest in Rhythm Pharmaceuticals has recently decreased by 9.00%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldRhythm Pharmaceuticals does not currently pay a dividend.Dividend GrowthRhythm Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRhythm Pharmaceuticals has received a 63.46% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Anti-obesity medication (A08)", "Clinical research services for deficiency diseases", and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Rhythm Pharmaceuticals is -1.80. Previous Next 2.5 News and Social Media Coverage News SentimentRhythm Pharmaceuticals has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Rhythm Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest2 people have searched for RYTM on MarketBeat in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rhythm Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $172,045.00 in company stock.Percentage Held by InsidersOnly 3.80% of the stock of Rhythm Pharmaceuticals is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Rhythm Pharmaceuticals are expected to grow in the coming year, from ($2.95) to ($2.02) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rhythm Pharmaceuticals is -5.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rhythm Pharmaceuticals is -5.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRhythm Pharmaceuticals has a P/B Ratio of 3.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Rhythm Pharmaceuticals (NASDAQ:RYTM) StockRhythm Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. The firm focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. Its product candidate includes setmelanotide, an MC4R agonist designed to restore impaired MC4R pathway function caused by genetic variants that occur upstream of the MC4R. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.Read More Receive RYTM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RYTM Stock News HeadlinesMarch 30, 2023 | marketwatch.comMobile Music Rhythm Games Market 2023 Huge Demand, Growth Opportunities and Expansion by 2029March 29, 2023 | marketwatch.comRhythm Energy Named Retail Energy Provider of the YearMarch 30, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.March 28, 2023 | marketwatch.comMobile Music Rhythm Games Market Demand and Competitive Analysis by Key Players to 2030| Tencent, C4Cat, T3 EntertainmentMarch 28, 2023 | marketwatch.comMobile Music Rhythm Games Market [ R and D ] till 2030March 27, 2023 | finance.yahoo.comRhythm Pharmaceuticals Announces Publication of Bardet-Biedl Syndrome Patient and Caregiver Perspectives of Hunger and Quality of Life with SetmelanotideMarch 21, 2023 | msn.comGeek Review: Rhythm SproutMarch 6, 2023 | nasdaq.comRhythm Pharmaceuticals Becomes Oversold (RYTM)March 30, 2023 | The Oxford Club (Ad)My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.March 3, 2023 | marketwatch.comCircadian Rhythm Sleep Disorders Market Size, Share & Trends Analysis Forecast Report by 2028March 2, 2023 | finance.yahoo.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q4 2022 Earnings Call TranscriptMarch 2, 2023 | msn.comBhopal: Students, teachers dance, audience clap, tap at ‘Rhythm 2k23’March 2, 2023 | finance.yahoo.comRhythm Pharmaceuticals Full Year 2022 Earnings: US$3.48 loss per share (vs US$1.40 loss in FY 2021)March 1, 2023 | marketwatch.comGlobal Cardiac Rhythm Management (CRM) Devices Market by Segment, Price Trend 2023-2028March 1, 2023 | msn.comRhythm Pharmaceuticals beats Q4 top and bottom line estimates; initiates FY23 outlookMarch 1, 2023 | finance.yahoo.comRhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial ResultsFebruary 28, 2023 | marketwatch.comCircadian Rhythm Sleep Treatment Market Size with Competitive Landscape, New Projects and Investment Analysis till 2028February 28, 2023 | marketwatch.comCircadian Rhythm Sleep Disorder Market Size 2023 With Strategic Choice-Making Process, Identification of Main CorporationsFebruary 27, 2023 | marketwatch.comCircadian Rhythm Sleep Disorder Market 2023 : Business Scenario, Corporate Profiles, Size and Dynamic Innovation by 2028February 27, 2023 | finanznachrichten.deRhythm Pharmaceuticals, Inc.: Rhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. and Portfolio of Investigational TherapeuticsFebruary 27, 2023 | finance.yahoo.comRhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. and Portfolio of Investigational TherapeuticsFebruary 23, 2023 | marketwatch.comGlobal Cardiac Rhythm Management Systems Market Analysis By Type Technology End-Use By Region By Country and Forecast 2023 to 2030 By VMReportsFebruary 22, 2023 | marketwatch.comCardiac Rhythm Management Device Market is Expected to Record Huge Growth, Emerging Trend, and Analysis by Top Prominent Players from 2023-2028February 21, 2023 | marketwatch.comCardiac Monitoring and Cardiac Rhythm Management Device Market Size, Outlook, Share, Prominent Players, Growth, and Forecast 2028February 21, 2023 | finance.yahoo.comRhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Wednesday, March 1, 2023February 21, 2023 | marketwatch.comElectronic Rhythm Machines Market Size with Competitive Landscape, New Projects and Investment Analysis till 2028February 17, 2023 | marketwatch.comCardiac Rhythm Management Market In 2023 By In-depth Analysis of Revenue Forecast and Competitive Landscape 2028See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive RYTM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RYTM Company Calendar Last Earnings3/01/2023Today3/30/2023Next Earnings (Estimated)5/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RYTM CUSIPN/A CIK1649904 Webwww.rhythmtx.com Phone(857) 264-4280Fax857-264-4299Employees140Year FoundedN/APrice Target and Rating Average Stock Price Forecast$36.00 High Stock Price Forecast$56.00 Low Stock Price Forecast$20.00 Forecasted Upside/Downside+106.4%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($3.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-181,120,000.00 Net Margins-766.22% Pretax Margin-766.22% Return on Equity-74.17% Return on Assets-54.28% Debt Debt-to-Equity RatioN/A Current Ratio8.90 Quick Ratio8.83 Sales & Book Value Annual Sales$23.64 million Price / Sales41.87 Cash FlowN/A Price / Cash FlowN/A Book Value$4.69 per share Price / Book3.72Miscellaneous Outstanding Shares56,750,000Free Float54,592,000Market Cap$989.72 million OptionableOptionable Beta1.82 Key ExecutivesDavid P. MeekerChairman, President & Chief Executive OfficerHunter C. SmithChief Financial Officer & TreasurerBrieana BuckleyVice President-Medical AffairsJoseph ShulmanChief Technical OfficerYann MazabraudExecutive Vice President & Head-InternationalKey CompetitorsCassava SciencesNASDAQ:SAVAArdelyxNASDAQ:ARDXBiohavenNYSE:BHVNDay One BiopharmaceuticalsNASDAQ:DAWNBiomea FusionNASDAQ:BMEAView All CompetitorsInsiders & InstitutionsState of WyomingBought 2,228 shares on 2/16/2023Ownership: 0.004%Squarepoint Ops LLCBought 7,144 shares on 2/15/2023Ownership: 0.116%State of Wisconsin Investment BoardBought 2,253 shares on 2/15/2023Ownership: 0.072%E Fund Management Co. Ltd.Sold 1,979 shares on 2/15/2023Ownership: 0.028%Legal & General Group PlcBought 5,028 shares on 2/15/2023Ownership: 0.026%View All Insider TransactionsView All Institutional Transactions RYTM Stock - Frequently Asked Questions Should I buy or sell Rhythm Pharmaceuticals stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RYTM shares. View RYTM analyst ratings or view top-rated stocks. What is Rhythm Pharmaceuticals' stock price forecast for 2023? 6 analysts have issued 1 year target prices for Rhythm Pharmaceuticals' stock. Their RYTM share price forecasts range from $20.00 to $56.00. On average, they expect the company's share price to reach $36.00 in the next twelve months. This suggests a possible upside of 106.4% from the stock's current price. View analysts price targets for RYTM or view top-rated stocks among Wall Street analysts. How have RYTM shares performed in 2023? Rhythm Pharmaceuticals' stock was trading at $29.12 on January 1st, 2023. Since then, RYTM stock has decreased by 40.1% and is now trading at $17.44. View the best growth stocks for 2023 here. When is Rhythm Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023. View our RYTM earnings forecast. How were Rhythm Pharmaceuticals' earnings last quarter? Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) issued its earnings results on Wednesday, March, 1st. The company reported ($0.75) EPS for the quarter, topping the consensus estimate of ($0.82) by $0.07. The company earned $8.80 million during the quarter, compared to analyst estimates of $7.16 million. Rhythm Pharmaceuticals had a negative trailing twelve-month return on equity of 74.17% and a negative net margin of 766.22%. The business's quarterly revenue was up 388.9% on a year-over-year basis. During the same quarter last year, the business posted ($0.85) earnings per share. What ETFs hold Rhythm Pharmaceuticals' stock? ETFs with the largest weight of Rhythm Pharmaceuticals (NASDAQ:RYTM) stock in their portfolio include Invesco DWA Healthcare Momentum ETF (PTH), Virtus LifeSci Biotech Products ETF (BBP), Invesco DWA SmallCap Momentum ETF (DWAS), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), BlackRock Future Health ETF (BMED) and IQ Healthy Hearts ETF (HART). What other stocks do shareholders of Rhythm Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rhythm Pharmaceuticals investors own include VBI Vaccines (VBIV), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Viking Therapeutics (VKTX), Amarin (AMRN), Kadmon (KDMN), Pfizer (PFE), Sangamo Therapeutics (SGMO) and Sarepta Therapeutics (SRPT). When did Rhythm Pharmaceuticals IPO? (RYTM) raised $100 million in an initial public offering (IPO) on Thursday, October 5th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen acted as the underwriters for the IPO and Needham was co-manager. What is Rhythm Pharmaceuticals' stock symbol? Rhythm Pharmaceuticals trades on the NASDAQ under the ticker symbol "RYTM." Who are Rhythm Pharmaceuticals' major shareholders? Rhythm Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include RA Capital Management L.P. (9.79%), NEA Management Company LLC (8.71%), Alkeon Capital Management LLC (3.97%), Opaleye Management Inc. (1.30%), Assenagon Asset Management S.A. (0.82%) and Geode Capital Management LLC (0.81%). Insiders that own company stock include David P Meeker, Hunter C Smith, Jennifer Chien, Joseph Shulman, Nithya Desikan, Pamela J Cramer, Ra Capital Management, LP, Todd Foley, William T Roberts and Yann Mazabraud. View institutional ownership trends. How do I buy shares of Rhythm Pharmaceuticals? Shares of RYTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Rhythm Pharmaceuticals' stock price today? One share of RYTM stock can currently be purchased for approximately $17.44. How much money does Rhythm Pharmaceuticals make? Rhythm Pharmaceuticals (NASDAQ:RYTM) has a market capitalization of $989.72 million and generates $23.64 million in revenue each year. The company earns $-181,120,000.00 in net income (profit) each year or ($3.48) on an earnings per share basis. How many employees does Rhythm Pharmaceuticals have? The company employs 140 workers across the globe. How can I contact Rhythm Pharmaceuticals? Rhythm Pharmaceuticals' mailing address is 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116. The official website for the company is www.rhythmtx.com. The company can be reached via phone at (857) 264-4280, via email at hannah.deresiewicz@sternir.com, or via fax at 857-264-4299. This page (NASDAQ:RYTM) was last updated on 3/30/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.